Back
Postmenopausal osteoporosis: Assessment and management.
Journal article

Postmenopausal osteoporosis: Assessment and management.

  • Rizzoli R Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, 1211 Geneva 14, Switzerland. Electronic address: rene.rizzoli@unige.ch.
  • 2018-11-20
Published in:
  • Best practice & research. Clinical endocrinology & metabolism. - 2018
aging
bisphosphonates
denosumab
fracture
malnutrition
teriparatide
Bone Density
Bone Density Conservation Agents
Denosumab
Diphosphonates
Exercise Therapy
Female
Fractures, Bone
Humans
Osteoporosis, Postmenopausal
Quality of Life
Randomized Controlled Trials as Topic
Teriparatide
Vitamin D
English Osteoporosis increases the risk of fractures, which are associated with increased mortality and lower quality of life. Patients with prevalent fracture are at high risk to of sustaining another one. Optimal protein and calcium intakes, and vitamin D supplies, together with regular weight bearing physical exercise are the corner stones of fracture prevention. Evidence for anti-fracture efficacy of pharmacological interventions relies on results from randomised controlled trials in postmenopausal women with fractures as the primary outcome. Treatments with bone resorption inhibitors, like bisphosphonates or denosumab, and bone formation stimulator like teriparatide, reduce vertebral and non-vertebral fracture risk. A reduction in vertebral fracture risk can already be detected within a year after starting therapy.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/46703
Statistics
Document views: 29 File downloads: